Results 61 to 70 of about 1,115 (163)

Efficacy and safety of avatrombopag in the treatment of thrombocytopenia: a Meta-analysis

Zhongguo linchuang yanjiu
"Objective To evaluate the efficacy and safety of avatrombopag in the treatment of thrombocytopenia by Meta-analytic methods. Methods PubMed, Embase, Web of Science, Cochrane Library, Scopus, Ovid, ClinicalTrials.gov, CNKI, Wanfang, VIP, CBM database ...
PENG Jincheng, XIA Quan, LIU Changwei, PENG Can, FANG Ling
doaj   +1 more source

Real‐World Safety and Efficacy of Avatrombopag in Adults with Immune Thrombocytopenia: A Systematic Review and Meta‐Analysis

European Journal of Haematology, Volume 117, Issue 1, Page 174-185, July 2026.
ABSTRACT Objective This systematic review and meta‐analysis aimed to evaluate the risk of thromboembolic events and assess the overall safety and effectiveness of avatrombopag in adult patients with immune thrombocytopenia using real‐world evidence. Methods A systematic search was conducted following the PRISMA 2020 guidelines.
M. L. Lozano, D. Valcarcel
wiley   +1 more source

Case Report: Successful Avatrombopag Treatment for Two Cases of Anti-PD-1 Antibody-Induced Acquired Amegakaryocytic Thrombocytopenia

Frontiers in Pharmacology, 2022
Background: Anti-PD-1/PD-L1 immunotherapy has achieved impressive responses in multiple types of malignancies in recent years. However, immune-related adverse events (irAEs) occur and limit their continuous clinical use.
Xiaofang Tu, Ali Xue, Suye Wu, Mengmeng Jin, Pu Zhao, Hao Zhang   +5 more
doaj   +1 more source

Avatrombopag, a promising novel thrombopoietin receptor agonist for refractory/relapsed/intolerant non-severe aplastic anemia: a phase 2 single-arm clinical trial

Annals of Medicine, 2023
Introduction The therapeutic options for thrombocytopenia in non-severe aplastic anaemia (NSAA) are limited. Avatrombopag (AVA) is prescribed for thrombocytopenic diseases but not for NSAA.Methods Herein, we conducted a phase 2, non-randomized, single ...
Ziqi Wan, Miao Chen, Bing Han
doaj   +1 more source

Thrombopoietin Receptor Agonists Plus Immunosuppressive Therapy in Aplastic Anaemia: A Systematic Review and Meta‐Analysis

eJHaem, Volume 7, Issue 2, April 2026.
ABSTRACT Background Immunosuppressive therapy (IST) is standard first‐line treatment for severe aplastic anaemia (AA) in patients ineligible for allogeneic transplantation. Thrombopoietin receptor agonists (TPO‐RAs) are increasingly added to IST to improve haematologic recovery, but long‐term safety remains uncertain.
Elham Ashrafi, Lauren Young, Lucy C. Fox, Stephen B. Ting, Erica M. Wood, Zoe K. McQuilten   +5 more
wiley   +1 more source

Six‐Year Trends in Real‐World Data Use for Post‐Marketing Surveillance of New Medical Products in Japan

Clinical and Translational Science, Volume 19, Issue 2, February 2026.
ABSTRACT The Ministerial Ordinance on Good Post‐Marketing Study Practice for Drugs was amended by the Ministry of Health, Labour and Welfare (MHLW) in 2018 to clearly define post‐marketing database studies (DBS) as a measure of pharmacovigilance activities for approved medical products in Japan.
Suguru Okami, Kako Shimotsumagari, Yasunari Sadatsuki   +2 more
wiley   +1 more source

Pragmatic Clinical Trial of Fostamatinib as Second‐Line Therapy in Adult Patients With Immune Thrombocytopenia and Insufficient Response to Prior Therapy: The Fostamatinib FORTE Trial

eJHaem, Volume 7, Issue 4, August 2026.
Amber Afzal, Robert Kribs, Sumit Sawhney, Mohit Narang, Frances Blevins, Robert Numerof, Francois Di Trapani, Sherry Ladha, Ruchika Goel   +8 more
wiley   +1 more source

DataSheet1_Avatrombopag for the treatment of thrombocytopenia induced by chemotherapy in patients with solid tumors: A multicenter, open-label, single-arm trial.docx

, 2022
Objective: To explore the effect and safety of avatrombopag for chemotherapy-induced thrombocytopenia (CIT).Methods: This multicenter, open-label, single-arm trial enrolled CIT patients in eight centers from October 2020 to April 2021.
Liting Qian (9278642), Chunbao Zang (11102184), Yufei Zhao (775411), Jin Huang (146235), Changlu Hu (13866692), Bihong Zhan (13866698), Xiaofeng Zhu (36670), Kaiyang Ding (3840079), Yayun Cui (12567190), Yifu He (5881085), Congyin Tu (13866695)   +10 more
core   +1 more source

This Is Not a Myeloproliferative Neoplasm…

Pediatric Blood &Cancer, Volume 73, Issue 7, July 2026.
Stephanie Juané Kennedy
wiley   +1 more source

Case Report: A Rare Case of Thrombocytopenia in Pregnancy, due to Suspected Acquired Amegakaryocytic Thrombocytopenia

Case Reports in Medicine, Volume 2026, Issue 1, 2026.
Acquired amegakaryocytic thrombocytopenia (AAT) in pregnancy is rare, with only one case report previously published on this condition. Our case is a 33‐year‐old G3P2002 female with severe thrombocytopenia, suspected to be due to AAT, who was managed with eltrombopag, prednisone, and cyclosporine A. The patient delivered at 32 weeks due to preeclampsia
Nuong Truong, Layan Alrahmani, Kristen Krum, Kevin Barton, Phillip J. DeChirstopher, Ameet Kini, Samreen Fathima, Namisha Dhillon, Nicole Sprawka, Joana Lopes Perdigao, Srichandhana Rajamouli, Stephanie Rodriguez, Kalee Ahlin, Ann Lal, Semonti Nandi   +14 more
wiley   +1 more source